Research Study on Whether a Combination of 2 Medicines (NNC0194 0499 and Semaglutide) Works in People With Non-alcoholic Steatohepatitis (NASH)
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: NNC0194 0499 50 mg/mLDrug: Placebo (NNC0194-0499)Drug: NNC0174 0833 10 mg/mLDrug: NNC0174 0833 placebo
- Registration Number
- NCT05016882
- Lead Sponsor
- Novo Nordisk A/S
- Brief Summary
This study is being done to see if a combination of 2 medicines (called NNC0194-0499 and semaglutide) can reduce liver damage in patients with non alcoholic steatohepatitis (NASH).
NNC0194-0499 is a new medicine which works in the liver. Semaglutide is a well-known medicine, which is already used by doctors to treat type 2 diabetes in many countries. It also helps with weight loss and may reduce liver damage, and so prevent future liver complications. It works in a different way to NNC0194 0499. The 2 medicines may work better together than on their own.
The study will also look at a combination of semaglutide and another weight-loss medicine called NNC0174-0833, which may be another treatment option for NASH.
Each week, participants will get 2 injections. These could be 2 of the 3 medicines OR 1 of the medicines and a placebo OR 2 placebo injections. Which treatment participants get is decided by chance. A placebo is a dummy medicine which looks like the real medicine but doesn't contain any active medicine.
The study will last for about 19 months. Participants will have 14 clinic visits and 9 phone calls with the study doctor.
Participants will have 1 or 2 liver biopsies (tiny pieces of liver tissue) - one at the start (if participants have not had a biopsy recently) and one at the end of the study treatment.
Women: Women cannot take part if pregnant, breast-feeding or planning to become pregnant during the study period.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 698
- Aged greater than or equal to 18 years at the time of signing informed consent. In Republic of Korea, subjects must be aged greater than or equal to 19 years. In Japan, subjects must be aged greater than or equal to 20 years. In Singapore, subjects must be aged greater than or equal to 21 years.
- Histological evidence of NASH based on a central pathologist evaluation of the baseline liver biopsy. The baseline liver biopsy can be a historical biopsy obtained within 180 days prior to Visit 1.
- Histological evidence of fibrosis stage 2, 3 or 4 according to the NASH CRN classification based on a central pathologist evaluation of the baseline liver biopsy.
- Histological non-alcoholic fatty liver disease (NAFLD) activity score (NAS) greater than or equal to 4 for subjects with F2/F3 or greater than or equal to 3 for subjects with F4 based on a central pathologist evaluation of the baseline liver biopsy. All subjects must have a score of 1 or more in steatosis, lobular inflammation and hepatocyte ballooning.
- Documented causes of chronic liver disease other than NAFLD.
- Positive HBsAg, positive anti-HIV, positive HCV RNA at screening (V2A) or any known presence of HCV RNA or HBsAg within 2 years of screening (V2A).
- Presence or history of ascites more than grade 1, variceal bleeding, hepatic encephalopathy, spontaneous bacterial peritonitis or liver transplantation at V2A.
- For subjects with F4, presence or history of gastro-oesophageal varices more than or equal to grade 2 at V3. An oesophagogastroduodenoscopy performed no more than 52 weeks prior to V3 must be available at V3.
- Known or suspected excessive consumption of alcohol (more than 20 g/day for women or more than 30 g/day for men) or alcohol dependence (assessed by the Alcohol Use Disorders Identification Test (AUDIT questionnaire)).
- Treatment with vitamin E (at doses more than or equal to 800 IU/day) or pioglitazone or medications approved for the treatment of NASH which has not been at a stable dose in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A.
- Treatment with GLP-1 RAs within 90 days prior to V2A. Subjects with a historical liver biopsy taken more than 90 days prior to V2A are excluded if they receive treatment with GLP-1 RAs from time of biopsy until V2A.
- Treatment with glucose-lowering agent(s) (other than GLP-1 RAs), lipid-lowering medication or weight loss medication not stable in the opinion of the investigator in the period from 90 days prior to V2A. In addition, for subjects with a historical liver biopsy taken more than 90 days prior to V2A, treatment should be at a stable dose in the opinion of the investigator from time of biopsy until V2A.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description NNC0194-0499 7.5 mg + semaglutide 2.4 mg Semaglutide 3 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg Semaglutide placebo Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. NNC0194-0499 15 mg + semaglutide 2.4 mg Semaglutide 3 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg Semaglutide placebo Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg Semaglutide placebo Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg Semaglutide placebo Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. NNC0194-0499 7.5 mg + semaglutide 2.4 mg NNC0194 0499 50 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0194-0499) 7.5 mg + semaglutide placebo 2.4 mg Placebo (NNC0194-0499) Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. NNC0194-0499 15 mg + semaglutide 2.4 mg NNC0194 0499 50 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0194-0499) 15 mg + semaglutide placebo 2.4 mg Placebo (NNC0194-0499) Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. NNC0194-0499 30 mg + semaglutide 2.4 mg NNC0194 0499 50 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. NNC0194-0499 30 mg + semaglutide placebo 2.4 mg NNC0194 0499 50 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. NNC0194-0499 30 mg + semaglutide placebo 2.4 mg Semaglutide placebo Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg Placebo (NNC0194-0499) Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0194-0499) 30 mg + semaglutide 2.4 mg Semaglutide 3 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0194-0499) 30 mg + semaglutide placebo 2.4 mg Placebo (NNC0194-0499) Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. NNC0174-0833 2.4 mg + semaglutide 2.4 mg Semaglutide 3 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. NNC0174-0833 2.4 mg + semaglutide 2.4 mg NNC0174 0833 10 mg/mL Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections. Placebo (NNC0174-0833) 2.4 mg + semaglutide placebo 2.4 mg NNC0174 0833 placebo Each subject will receive two subcutaneous injections once weekly, consisting of two active drugs or one active drug and one placebo or two placebo injections.
- Primary Outcome Measures
Name Time Method Improvement in liver fibrosis and no worsening of NASH (Yes/No) From baseline (week 0) to week 52 Count of subjects Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale
- Secondary Outcome Measures
Name Time Method Number of treatment emergent adverse events (TEAEs) From baseline (week 0) to week 59 Count
Improvement in liver fibrosis (Yes/No) From baseline (week 0) to week 52 Count of subjects Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scale
Progression of liver fibrosis (Yes/No) From baseline (week 0) to week 52 Count of subjects For subjects with fibrosis stage 2 or 3 at baseline
Worsening in steatohepatitis (Yes/No) From baseline (week 0) to week 52 Count of subjects Worsening in steatohepatitis is defined as increase in NAS score for ballooning, inflammation or steatosis
Improvement in ballooning (Yes/No) From baseline (week 0) to week 52 Count of subjects
Improvement in inflammation (Yes/No) From baseline (week 0) to week 52 Count of subjects
Improvement in steatosis (Yes/No) From baseline (week 0) to week 52 Count of subjects
Change in ALT (alanine aminotransferase) From baseline (week 0) to week 52 Ratio to baseline
Change in AST (aspartate aminotransferase) From baseline (week 0) to week 52 Ratio to baseline
Resolution of steatohepatitis and no worsening of liver fibrosis (Yes/No) From baseline (week 0) to week 52 Count of subjects Resolution of steatohepatitis is defined as a NAS of 0-1 for inflammation, 0 for ballooning and any value for steatosis according to NASH CRN52. Fibrosis is graded on the NASH CRN (Non-Alcoholic Steatohepatitis Clinical Research Network) fibrosis scale from 0 to 4.
Improvement in steatohepatitis with at least a 2-point reduction in NAS and no worsening of fibrosis (Yes/No) From baseline (week 0) to week 52 Count of subjects The 2-point reduction must include at least a 1-point reduction in either lobular inflammation or hepatocellular ballooning.
Change in histology-assessed liver collagen proportionate area From baseline (week 0) to week 52 Ratio to baseline
Resolution of steatohepatitis and improvement in liver fibrosis (Yes/No) From baseline (week 0) to week 52 Count of subjects Resolution of steatohepatitis is defined as an NAS score of 0-1 for inflammation, 0 for ballooning and any value for steatosis (according to NASH CRN).
Improvement in fibrosis is defined as greater than or equal to 1 grade improvement on the NASH CRN fibrosis scaleChange in inflammation assessed by HsCRP (high sensitivity C-reactive protein) From baseline (week 0) to week 52 Ratio to baseline
Change in ELF (Enhanced Liver Fibrosis) score From baseline (week 0) to week 52 Logarithm
Change in HbA1c. For subjects with type 2 diabetes From baseline (week 0) to week 52 %-points (absolute change)
Change in triglycerides From baseline (week 0) to week 52 Ratio to baseline
Change in free fatty acids From baseline (week 0) to week 52 Ratio to baseline
Change in LDL (low density lipoprotein) cholesterol From baseline (week 0) to week 52 Ratio to baseline
Change in HDL (high density lipoprotein) cholesterol From baseline (week 0) to week 52 Ratio to baseline
Relative change in body weight From baseline (week 0) to week 52 Percentage
Change in SF-36 (36-item Short Form Survey) bodily pain From baseline (week 0) to week 52 Points
Change in NASH-CHECK (patient-reported outcome measure for non-alcoholic steatohepatitis)pain From baseline (week 0) to week 52 Points
Change in PROMIS (Patient-Reported Outcomes Measurement Information System) Fatigue score From baseline (week 0) to week 52 Points
Trial Locations
- Locations (183)
Gastroenterology Assoc_ CGA
🇺🇸Macon, Georgia, United States
Gastroint Spec of Georgia
🇺🇸Marietta, Georgia, United States
Texas Diabetes &Endocrinology
🇺🇸Round Rock, Texas, United States
Olympus Clinical Research
🇺🇸Sugar Land, Texas, United States
St Vincent's Hospital (Melbourne)
🇦🇺Fitzroy, Victoria, Australia
Krajská nemocice Liberec, a.s
🇨🇿Liberec, Czechia
Abdominal Center K, Research Unit
🇩🇰København NV, Denmark
Gen Hospital of Athens Laiko,1st Dpt. of Propaedeutic Inter
🇬🇷Athens, Greece
General Hospital of Athens "LAIKO"
🇬🇷Goudi, Athens, Greece
"AHEPA" University Hospital of Thessaloniki
🇬🇷Thessaloniki, Greece
General Hospital of Thessaloniki "Ippokrateio"
🇬🇷Thessaloniki, Greece
Surat Institute of Digestive Science
🇮🇳Surat, Gujarat, India
Hamamatsu University Hospital
🇯🇵Hamamatsu-shi, Shizuoka, Japan
JA Hiroshima General Hospital
🇯🇵Hatsukaichi-shi, Hiroshima, Japan
University Hospital Kyoto Prefectual University of Medicine
🇯🇵Kamigyo-ku, Kyoto, Japan
Optimus U, Corp
🇺🇸Miami, Florida, United States
Univ of Miami/Schiff Ctr
🇺🇸Miami, Florida, United States
Covenant Metabolic Specialists LLC
🇺🇸University Park, Florida, United States
Florida Medical Clinic Orlando Health
🇺🇸Zephyrhills, Florida, United States
Florida Medical Clinic, LLC
🇺🇸Zephyrhills, Florida, United States
Piedmont Healthcare
🇺🇸Atlanta, Georgia, United States
Digestive Healthcare of Georgia
🇺🇸Atlanta, Georgia, United States
Miguel Rebollar PA
🇺🇸Hialeah, Florida, United States
Nature Coast Clinical Research_Inverness
🇺🇸Inverness, Florida, United States
Florida Research Institute, LLC
🇺🇸Lakewood Ranch, Florida, United States
Digestive Research Alliance of Michiana
🇺🇸South Bend, Indiana, United States
University Of Kansas Hospital
🇺🇸Kansas City, Kansas, United States
Kansas Medical Clinic, PA
🇺🇸Topeka, Kansas, United States
Tandem Clinical Research - Houma
🇺🇸Houma, Louisiana, United States
Tandem Clinical Research
🇺🇸Marrero, Louisiana, United States
Louisiana Research Center, LLC
🇺🇸Shreveport, Louisiana, United States
Mercy Medical Center, GI Research
🇺🇸Baltimore, Maryland, United States
Walter Reed Nat Mil Md Ctr
🇺🇸Bethesda, Maryland, United States
Univ Hosp Cleveland Med Ctr
🇺🇸Cleveland, Ohio, United States
Henry Ford Hospital_Detroit
🇺🇸Detroit, Michigan, United States
Kansas City Research Institute
🇺🇸Kansas City, Missouri, United States
AIG Digestive Disease Research
🇺🇸Florham Park, New Jersey, United States
NYU Grossman School of Med
🇺🇸New York, New York, United States
Weill Cornell Med Coll-NYPH
🇺🇸New York, New York, United States
Ohio State Univ Wexner Med Ctr
🇺🇸Columbus, Ohio, United States
DSI Research,LLC
🇺🇸Springboro, Ohio, United States
UPMC_Center for Liver Care
🇺🇸Pittsburgh, Pennsylvania, United States
Amer. Rrsch Corp-TX Liver Inst
🇺🇸San Antonio, Texas, United States
Geisinger Clinic
🇺🇸Danville, Pennsylvania, United States
UPMC Center for Liver Diseases
🇺🇸Pittsburgh, Pennsylvania, United States
Digestive Health Res-TSMC
🇺🇸Hermitage, Tennessee, United States
Quality Medical Research
🇺🇸Nashville, Tennessee, United States
Liver Institute NW
🇺🇸Seattle, Washington, United States
Genesis Research Services
🇦🇺Broadmeadow, New South Wales, Australia
Pennsylvania State University
🇺🇸Hershey, Pennsylvania, United States
University of Pennsylvania Hospital
🇺🇸Philadelphia, Pennsylvania, United States
Texas Clin Res Inst, LLC
🇺🇸Arlington, Texas, United States
Thomas Jefferson University Hospital
🇺🇸Philadelphia, Pennsylvania, United States
Liver Ins@ Mthdist DTX Med Cen
🇺🇸Dallas, Texas, United States
Digestive Hlth Res of N Texas
🇺🇸Wichita Falls, Texas, United States
Bon Secours Richmond Community Hospital LLC
🇺🇸Richmond, Virginia, United States
Impact Research
🇺🇸Waco, Texas, United States
Inova Fairfax Medical Campus
🇺🇸Falls Church, Virginia, United States
Gastroent Consult of SW VA
🇺🇸Roanoke, Virginia, United States
Swedish med ctr org trans-lvr ctr
🇺🇸Seattle, Washington, United States
St Vincent's Hospital
🇦🇺Darlinghurst, New South Wales, Australia
Nepean Hospital
🇦🇺Kingswood, New South Wales, Australia
Westmead Hospital
🇦🇺Westmead, New South Wales, Australia
Royal Adelaide Hospital - Hepatology- 5E291
🇦🇺Adelaide, South Australia, Australia
Monash Health Department of Gastroenterology
🇦🇺Clayton, Victoria, Australia
Austin Health
🇦🇺Heidelberg, Victoria, Australia
The Alfred Centre - Gastroenterology
🇦🇺Melbourne, Victoria, Australia
Fiona Stanley Hospital - Hepatology
🇦🇺Murdoch, Western Australia, Australia
CUB Hôpital Erasme_Brussels_0
🇧🇪Bruxelles, Belgium
Cliniques Universitaires Saint-Luc - Serv. Hépato-gastroentérology
🇧🇪Bruxelles, Belgium
UZA
🇧🇪Edegem, Belgium
UZ Gent - Department Gastro-enterology
🇧🇪Gent, Belgium
"Acibadem City Clinic UMHAT Tokuda"
🇧🇬Sofia, Bulgaria
UMHAT "Sv. Ivan Rilski", Clinic of Gastroenterology
🇧🇬Sofia, Bulgaria
"DCC XX - Sofia" EOOD
🇧🇬Sofia, Bulgaria
University of Calgary Liver Unit-(HMRC)
🇨🇦Calgary, Alberta, Canada
GI Research Inst Foundation
🇨🇦Vancouver, British Columbia, Canada
Toronto Liver Centre
🇨🇦Toronto, Ontario, Canada
Hvidovre Hospital - Gastroenheden
🇩🇰Hvidovre, Denmark
Odense University Hospital
🇩🇰Odense C, Denmark
Centre Hospitalier Universitaire D'Angers-1
🇫🇷Angers, France
Ap-Hp-Hopital Beaujon
🇫🇷Clichy, France
Hospices Civils de Lyon-Hopital de La Croix Rousse
🇫🇷Lyon Cedex 4, France
Centre Hospitalier Universitaire de Nice-Hopital de L'Archet 2
🇫🇷Nice, France
Aphp-Hopital La Pitie Salpetriere-4
🇫🇷Paris, France
Centre Hospitalier Universitaire de Nantes-Hopital Nord Laennec-1
🇫🇷Saint Herblain, France
Centre de Recherche Clinique Portes Du Sud
🇫🇷Venissieux, France
Klinik für Endokrinologie, Diabetologie und Stoffwechsel
🇩🇪Essen, Germany
Universitätsklinikum Schleswig-Holstein - Medizinischen Klinik I am Campus Lübeck
🇩🇪Lübeck, Germany
Universitätsklinikum Schleswig-Holstein
🇩🇪Lübeck, Germany
Universitätsmedizin der Johannes-Gutenberg-Universität Mainz - Hepatologie
🇩🇪Mainz, Germany
Universitätsklinikum Würzburg, Zentrum für Innere Medizin (ZIM)
🇩🇪Würzburg, Germany
Universitätsklinikum Würzburg, ZIM
🇩🇪Würzburg, Germany
Gen Hospital of Athens Ippokrateio,B' Uni Clinic of Inte Med
🇬🇷Athens, Greece
Yashoda Hospital
🇮🇳Secunderabad, Andhra Pradesh, India
BAPS Pramukh Swami Hospital
🇮🇳Surat, Gujarat, India
Medanta - The Medicity Multi-Speciality Hospital, Gurugram
🇮🇳Gurugram, Haryana, India
Kasturba Medical College Hospitals (KMC Hospitals), Mangalore
🇮🇳Mangalore, Karnataka, India
Gleneagles Hospital, Super-speciality and Transplant Centre, Parel
🇮🇳Mumbai, Maharashtra, India
Seth GS medical college and KEM Hospital
🇮🇳Mumbai, Maharashtra, India
S.R.Kalla Memorial Gastro & General Hospital
🇮🇳Jaipur, Rajasthan, India
Midas Multispeciality Hospital
🇮🇳Nagpur, Maharashtra, India
Institute of liver and Biliary Sciences
🇮🇳Ghitorni, New Delhi, India
Dr P V Rao - Diabetes Research Centre
🇮🇳Hyderabad, Telangana, India
Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona
🇮🇹Ancona, Italy
All India Institute of medical Sciences
🇮🇳New Dehli, New Delhi, India
Fortis Heart Institute and Multispeciality Hospital
🇮🇳Chandigarh,, Punjab, India
Post Graduate Institute of Medical Education & Research_Chandigarh
🇮🇳Chandigarh, Punjab, India
Osmania General Hospital
🇮🇳Hyderabad, Telagana, India
Azienda Ospedaliera di Padova Clin.Med.3
🇮🇹Padova, Italy
AOU Pisana Stabilimento di Cisanello EDIFICIO 6, Piano 5
🇮🇹Pisa, Italy
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
🇮🇹Roma, Italy
Policlinico Università Campus Biomedico di Roma
🇮🇹Rome, Italy
Chiba University Hospital_Chiba-shi, Chiba
🇯🇵Chiba-shi, Chiba, Japan
Azienda Socio Sanitaria Territoriale (ASST) Papa Giovanni XXIII
🇮🇹Bergamo, Italy
Azieda Ospedaliero-Universitaria, Policlinico S. Orsola-Malp
🇮🇹Bologna, Italy
AOU Careggi Padiglione 16 San Luca, 3° piano
🇮🇹Firenze, Italy
Fukui-ken Saiseikai Hospital, Internal Medicine
🇯🇵Fukui-shi, Fukui, Japan
St. Marianna University School of Medicine Hospital
🇯🇵Kawasaki-shi, Kanagawa, Japan
Kumamoto Shinto General Hospital
🇯🇵Kumamoto-shi, Kumamoto, Japan
Toranomon Hospital, Hepatology
🇯🇵Minato-ku, Tokyo, Japan
Kawasaki Medical School General Medical Center
🇯🇵Okayama-shi, Okayama, Japan
Saga University Hospital_Liver Center
🇯🇵Saga-shi, Saga, Japan
Sendai Kousei Hospital
🇯🇵Sendai-shi, Miyagi, Japan
Saiseikai Suita Hospital, Gastroenterology
🇯🇵Suita-shi, Osaka, Japan
Ehime University Hospital
🇯🇵Toon-shi, Ehime, Japan
Saiseikai Wakayama Hospital
🇯🇵Wakayama-shi, Wakayama, Japan
Yokohama City University Hospital, Gastrointestinal Medicine
🇯🇵Yokohama-shi, Kanagawa, Japan
Korea University Ansan Hospital
🇰🇷Ansan, Gyeonggi-do, Korea, Republic of
Kyungpook National University Hospital
🇰🇷Daegu, Korea, Republic of
Yeungnam Univ. Medical Center
🇰🇷Daegu, Korea, Republic of
Wonju Severance Christian Hospital
🇰🇷Gangwon-do, Korea, Republic of
Severance Hospital, Yonsei University Health System
🇰🇷Seoul, Korea, Republic of
SMG-SNU Boramae Medical Center
🇰🇷Seoul, Korea, Republic of
Korea University Guro Hospital
🇰🇷Seoul, Korea, Republic of
Hospital Universiti Sains Malaysia
🇲🇾Kota Bharu, Kelantan, Malaysia
University Malaya Medical Centre
🇲🇾Kuala Lumpur, Wilayah Persekutuan Kuala Lumpur, Malaysia
Hospital Selayang
🇲🇾Batu Caves, Malaysia
ID Clinic Arkadiusz Pisula
🇵🇱Mysłowice, Malopolskie, Poland
Spolka Lekarzy Intercor Sp. z o.o.
🇵🇱Bydgoszcz, Poland
Clinical Medical Research Korfantego - Ambulatoryjna Opieka
🇵🇱Katowice, Poland
Uniwersyteckie Centrum Kliniczne im. Prof. K. Gibińskiego Śl
🇵🇱Katowice, Poland
Hacettepe Universitesi Tıp Fakültesi- Gastroenteroloji
🇹🇷Ankara, Turkey
Krakowskie Centrum Medyczne Sp. z o.o.
🇵🇱Krakow, Poland
"LANDA" Katarzyna Agata Landa
🇵🇱Kraków, Poland
EMC Instytut Medyczny S.A.
🇵🇱Wroclaw, Poland
Centrum Badan Klinicznych
🇵🇱Wroclaw, Poland
FutureMeds Sp. z o.o.
🇵🇱Wroclaw, Poland
Velocity Nova Sp. z o.o.
🇵🇱Staszow, Świętokrzyskie, Poland
Unidade Local De Saude De Matosinhos E.P.E.
🇵🇹Senhora Da Hora, Matosinhos, Matosinhos, Portugal
Unidade Local De Saude De Santa Maria E.P.E.
🇵🇹Lisboa, Portugal
FDI Clinical Research
🇵🇷San Juan, Puerto Rico
Penza Regional Clinical Hospital named after N.N. Burdenko
🇷🇺Penza, Russian Federation
National University Hospital_TBD
🇸🇬Singapore, Singapore
Singapore General Hospital
🇸🇬Singapore, Singapore
Changi General Hospital
🇸🇬Singapore, Singapore
Complejo Hospitalario de Pontevedra - Hospital de Montecelo
🇪🇸Pontevedra, Galicia, Spain
Hospital Vall d'Hebron
🇪🇸Barcelona, Spain
Hospital Universitario Marqués de Valdecilla
🇪🇸Santander, Spain
Gazi University Medical Faculty
🇹🇷Ankara, Turkey
Hospital Virgen del RocÃo
🇪🇸Sevilla, Spain
Hospital ClÃnico de Valladolid
🇪🇸Valladolid, Spain
Kaohsiung Medical University Chung-Ho Memorial Hospital
🇨🇳Kaohsiung, Taiwan
National Cheng Kung University Hospital
🇨🇳Tainan, Taiwan
National Taiwan University Hospital
🇨🇳Taipei, Taiwan
T.C. Saglık Bakanlıgı Adana Sehir Egitim ve Arastirma Hastan
🇹🇷Adana, Turkey
Bezmialem Vakif Universitesi Tip Fakultesi Hastanesi-Gastroe
🇹🇷Istanbul, Turkey
Marmara Univ. Pendik Gastroenterology
🇹🇷Istanbul, Turkey
Kocaeli Universitesi Tıp Fakültesi Gastroenteroloji ve Hepat
🇹🇷Kocaeli, Turkey
Royal Devon & Exeter NHS Foundation Trust
🇬🇧Exeter, United Kingdom
Keimyung University Dongsan Hospital
🇰🇷Daegu, Korea, Republic of
The Institute for Liver Health
🇺🇸Chandler, Arizona, United States
North AL Health Res, LLC
🇺🇸Huntsville, Alabama, United States
Inst-Liver Hlth dba AZ Liver H
🇺🇸Peoria, Arizona, United States
UCSD NAFLD Research Center
🇺🇸La Jolla, California, United States
Del Sol Research Management, LLC
🇺🇸Tucson, Arizona, United States
OM Research LLC
🇺🇸Lancaster, California, United States
Stanford Medicine
🇺🇸Redwood City, California, United States
UC Davis Hlth -Midtwn Ambu Cen
🇺🇸Sacramento, California, United States
Peak Gastro Assoc-Col Springs
🇺🇸Colorado Springs, Colorado, United States
Integrity Clinical Research, LLC
🇺🇸Doral, Florida, United States
Hartford Hsptl_Hartford
🇺🇸Hartford, Connecticut, United States
UF Hlth Jacksonville
🇺🇸Jacksonville, Florida, United States